Download Documentation Q3 2016 Earnings Conference Call Presentation

Corporate Profile

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our 17-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston, New York, and our field team.

Stock Quote

KERX (Common)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.05 (0.84%)
Data as of 12/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Report

View the 2015 Annual Report on Form 10K  - PDF View the 2015 Annual Report on Form 10K

Recent News

11/18/16Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney WeekPrinter Friendly Version
11/17/16Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)Printer Friendly Version
11/09/16Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia® (ferric citrate)Printer Friendly Version
11/09/16Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.